Sanmai Pharma

Sanmai Pharma is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the discovery and development of innovative therapies using Targeted Protein Degradation (TPD) technology. The company's primary focus is on creating next-generation small molecules, including Proteolysis-Targeting Chimeras (PROTACs) and molecular glues, to address unmet medical needs in oncology and autoimmune diseases. Sanmai's lead program, SM-01, is an AR-targeting PROTAC currently in clinical development for the treatment of metastatic castration-resistant prostate cancer. The company's pipeline also features programs targeting Bruton's Tyrosine Kinase (BTK) and GSPT1, aimed at overcoming resistance to existing therapies. By leveraging its proprietary TPD platform, Sanmai Pharma aims to degrade "undruggable" targets and provide transformative treatments for patients with difficult-to-treat malignancies. The company is led by a team of experts in medicinal chemistry and is supported by prominent venture capital investors.